高盛将赣锋锂业H股评级从中性下调至卖出，理由是锂现货价格面临下行风险，因下游市场短期反馈欠 佳以及补库存增速放缓。 ...

Core Insights - Microsoft and Amazon experienced significant negative reactions following downgrades from Rothschild & Co. earlier in the week [1] Company Reactions - Both companies faced substantial downgrades which impacted their stock performance negatively [1]

Group 1 - Kering's stock price fell by 4.1%, making it the worst performer in the French CAC 40 index [1] - This decline marks the worst single-day performance since mid-June [1] - The drop in stock price was triggered by HSBC downgrading its rating from "Buy" to "Hold" [1]

Group 1 - HP's shares fell approximately 3% in premarket trading following a downgrade by J.P. Morgan [3] - J.P. Morgan has changed its rating on HP Inc. from Overweight to Neutral [3] - The firm has set a price target of $30 for HP's stock [3]

Core Viewpoint - FedEx Corp's stock has declined by 2% to $237.44 following a downgrade from J.P. Morgan Securities, which changed its rating from "overweight" to "neutral" and reduced the price target from $284 to $274, citing high costs associated with separating the freight segment and recent operational underperformance [1] Group 1: Analyst Ratings and Price Targets - Despite the downgrade, 18 out of 30 analysts still rate FedEx as a "buy" or better, with a 12-month consensus target price of $266.06, representing an 11.9% premium over current levels, indicating potential for further downgrades or price-target cuts [2] - FedEx has faced challenges in overcoming resistance at the $250 level for several months, currently showing a 15.5% year-to-date deficit [3] Group 2: Market Sentiment and Options Activity - The options market has exhibited a more bearish sentiment than usual over the past 10 weeks, with a 50-day put/call volume ratio of 1.03, which is higher than 99% of annual readings [4] - The current Schaeffer's Volatility Index (SVI) for FedEx is at 28%, placing it in the 13th percentile of annual readings, suggesting that options traders are anticipating low volatility [5]

Group 1 - GE Vernova Inc. shares fell over 2% after RBC Capital downgraded the stock to Sector Perform from Outperform [1] - RBC Capital cut the price target for GE Vernova to $605 from $631 [1] - The downgrade reflects that the strong demand in energy generation and distribution, along with favorable pricing and productivity gains, are already priced into the stock's valuation and consensus forecasts [1] Group 2 - The $605 price target is based on 13 times RBC's 2030 EBITDA forecast of $12.2 billion, which is approximately 4% below consensus estimates [2]

Core Viewpoint - BMO analyst Fadi Chamoun has downgraded UPS shares from Buy to Hold, indicating a more cautious outlook on the company's performance [1]. Summary by Category Analyst Rating Changes - The rating on UPS shares has been cut to Hold from Buy [1]. - The price target for UPS shares has been reduced from $125 to $96 [1].

Core Viewpoint - Evercore ISI has downgraded FedEx shares from Buy to Hold, indicating a shift in investment sentiment towards the company [1] Company Summary - The downgrade reflects concerns regarding FedEx's future performance and market conditions that may impact its profitability [1]

Core Viewpoint - Jefferies analyst David Windley downgraded Icon PLC (ICLR.US) from "Buy" to "Hold" and reduced the target price from $220 to $175, citing excessive unfavorable factors facing the company [1] Group 1: Company Performance - Windley believes that despite Icon PLC's stock being "cheap," there may be further downward revisions to earnings expectations [1] - Ongoing channel surveys indicate that Icon PLC is losing market share, which undermines the growth momentum gained from winning four partnership agreements since the merger with PRA Health [1] Group 2: Financial Outlook - Jefferies estimates that the amount of customer order cancellations in the third quarter could approach $1 billion, with a possibility of maintaining high levels in the fourth quarter [1] Group 3: Company Overview - Icon PLC is a clinical research organization that provides outsourced research and development services for the biotechnology, pharmaceutical, and medical device industries, focusing on managing, developing, and analyzing clinical development-related projects [1]

Group 1 - Goldman Sachs downgraded Novartis' stock rating from "Neutral" to "Sell," indicating a negative outlook for the stock [1] - The target price for Novartis was slightly reduced from 95.00 CHF to 94.00 CHF, suggesting a weak price trajectory over the next 12 months [1] - Concerns were raised regarding Novartis' growth rate due to increasing competition in the generic drug market, leading to a structural adjustment in overall growth expectations [1] Group 2 - Despite growth concerns, Novartis maintains a strong financial health score, with a revenue growth of 12.95% over the past twelve months [1] - Current trading prices for Novartis are around 101 CHF in Europe and 127.70 USD in the US ADR market [1] - The stock's performance includes a pre-market decline of nearly 3%, with a recent pre-market price of 124.18 USD [1]